| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 76 | 2025 | 559 | 15.500 |
Why?
|
| Mycobacterium tuberculosis | 55 | 2025 | 413 | 10.080 |
Why?
|
| Tuberculosis, Pulmonary | 34 | 2025 | 228 | 9.320 |
Why?
|
| HIV Infections | 33 | 2025 | 2063 | 4.730 |
Why?
|
| Contact Tracing | 12 | 2025 | 56 | 4.380 |
Why?
|
| Antitubercular Agents | 30 | 2025 | 264 | 3.250 |
Why?
|
| Interferon-gamma Release Tests | 14 | 2025 | 89 | 3.230 |
Why?
|
| Tuberculin Test | 19 | 2024 | 123 | 2.690 |
Why?
|
| Latent Tuberculosis | 9 | 2019 | 76 | 2.480 |
Why?
|
| Isoniazid | 10 | 2022 | 66 | 2.360 |
Why?
|
| Sputum | 14 | 2025 | 116 | 2.200 |
Why?
|
| Feces | 10 | 2025 | 780 | 1.960 |
Why?
|
| Sensitivity and Specificity | 24 | 2025 | 2145 | 1.930 |
Why?
|
| Family Characteristics | 10 | 2021 | 91 | 1.910 |
Why?
|
| Mass Screening | 13 | 2025 | 831 | 1.870 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2024 | 179 | 1.760 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2025 | 544 | 1.640 |
Why?
|
| Child, Preschool | 63 | 2025 | 14851 | 1.570 |
Why?
|
| Child | 76 | 2025 | 25823 | 1.540 |
Why?
|
| Interferon-gamma | 10 | 2025 | 539 | 1.410 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 10 | 2025 | 76 | 1.390 |
Why?
|
| Adolescent | 56 | 2025 | 20552 | 1.360 |
Why?
|
| BCG Vaccine | 10 | 2024 | 112 | 1.340 |
Why?
|
| Adoption | 5 | 2011 | 18 | 1.300 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 351 | 1.270 |
Why?
|
| Emigrants and Immigrants | 5 | 2015 | 157 | 1.180 |
Why?
|
| Humans | 134 | 2025 | 132334 | 1.130 |
Why?
|
| Infant | 44 | 2025 | 13192 | 1.060 |
Why?
|
| South Africa | 17 | 2021 | 107 | 1.010 |
Why?
|
| Disease Transmission, Infectious | 4 | 2020 | 86 | 0.900 |
Why?
|
| Diarylquinolines | 1 | 2023 | 6 | 0.850 |
Why?
|
| Male | 64 | 2025 | 65052 | 0.780 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2019 | 134 | 0.780 |
Why?
|
| HIV-1 | 3 | 2020 | 482 | 0.770 |
Why?
|
| Tanzania | 6 | 2024 | 73 | 0.750 |
Why?
|
| Global Health | 9 | 2023 | 619 | 0.740 |
Why?
|
| West Nile Fever | 4 | 2008 | 139 | 0.730 |
Why?
|
| Female | 63 | 2025 | 70786 | 0.730 |
Why?
|
| Symptom Assessment | 1 | 2021 | 109 | 0.690 |
Why?
|
| Communicable Disease Control | 3 | 2017 | 141 | 0.680 |
Why?
|
| Prospective Studies | 18 | 2025 | 6540 | 0.670 |
Why?
|
| DNA Methylation | 3 | 2024 | 1132 | 0.630 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 830 | 0.620 |
Why?
|
| Orphanages | 1 | 2019 | 7 | 0.620 |
Why?
|
| Radiography, Thoracic | 4 | 2021 | 153 | 0.620 |
Why?
|
| Lung Diseases | 1 | 2023 | 409 | 0.600 |
Why?
|
| Leukocytes | 1 | 2020 | 210 | 0.600 |
Why?
|
| Child, Orphaned | 1 | 2019 | 21 | 0.600 |
Why?
|
| T-Lymphocytes | 5 | 2025 | 1759 | 0.590 |
Why?
|
| Coinfection | 6 | 2025 | 189 | 0.570 |
Why?
|
| Forecasting | 2 | 2017 | 373 | 0.570 |
Why?
|
| Bacteriological Techniques | 4 | 2016 | 89 | 0.560 |
Why?
|
| Mycobacterium bovis | 3 | 2022 | 32 | 0.560 |
Why?
|
| DNA, Bacterial | 5 | 2024 | 494 | 0.550 |
Why?
|
| Tuberculosis, Lymph Node | 3 | 2022 | 20 | 0.550 |
Why?
|
| Adult | 33 | 2025 | 31618 | 0.540 |
Why?
|
| Medication Adherence | 1 | 2020 | 326 | 0.540 |
Why?
|
| Young Adult | 16 | 2025 | 9945 | 0.530 |
Why?
|
| West Nile virus | 3 | 2008 | 117 | 0.530 |
Why?
|
| Environmental Exposure | 3 | 2019 | 236 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 300 | 0.520 |
Why?
|
| Skin Tests | 3 | 2009 | 80 | 0.510 |
Why?
|
| Africa South of the Sahara | 5 | 2025 | 124 | 0.500 |
Why?
|
| Pediatrics | 4 | 2018 | 1215 | 0.490 |
Why?
|
| Nutritional Status | 3 | 2017 | 328 | 0.470 |
Why?
|
| Emigration and Immigration | 2 | 2007 | 83 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 379 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 390 | 0.460 |
Why?
|
| Lipopolysaccharides | 3 | 2025 | 306 | 0.450 |
Why?
|
| HIV Seropositivity | 3 | 2021 | 129 | 0.440 |
Why?
|
| Transients and Migrants | 2 | 2025 | 26 | 0.440 |
Why?
|
| Candidiasis | 2 | 2009 | 137 | 0.430 |
Why?
|
| Rifampin | 4 | 2022 | 120 | 0.420 |
Why?
|
| Age Factors | 9 | 2024 | 2931 | 0.420 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2019 | 138 | 0.420 |
Why?
|
| Uganda | 6 | 2025 | 89 | 0.400 |
Why?
|
| Cohort Studies | 6 | 2023 | 5150 | 0.390 |
Why?
|
| Internationality | 2 | 2011 | 133 | 0.390 |
Why?
|
| Pandemics | 1 | 2020 | 1188 | 0.390 |
Why?
|
| Mozambique | 4 | 2025 | 23 | 0.390 |
Why?
|
| Child Behavior | 3 | 2021 | 235 | 0.390 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 59 | 0.390 |
Why?
|
| Health Personnel | 3 | 2025 | 546 | 0.380 |
Why?
|
| Models, Economic | 1 | 2012 | 55 | 0.380 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2022 | 34 | 0.370 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2446 | 0.360 |
Why?
|
| Tuberculosis, Meningeal | 2 | 2022 | 28 | 0.350 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2016 | 356 | 0.350 |
Why?
|
| Social Stigma | 3 | 2024 | 85 | 0.340 |
Why?
|
| Ascariasis | 3 | 2018 | 73 | 0.340 |
Why?
|
| Antigens, Bacterial | 5 | 2025 | 325 | 0.340 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 3742 | 0.340 |
Why?
|
| Reference Standards | 4 | 2021 | 242 | 0.340 |
Why?
|
| Predictive Value of Tests | 6 | 2025 | 2303 | 0.330 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 151 | 0.330 |
Why?
|
| Risk Assessment | 8 | 2020 | 3710 | 0.320 |
Why?
|
| Reproducibility of Results | 5 | 2025 | 3022 | 0.320 |
Why?
|
| Qualitative Research | 3 | 2025 | 664 | 0.320 |
Why?
|
| Infant, Newborn | 8 | 2024 | 8566 | 0.320 |
Why?
|
| Poliomyelitis | 1 | 2009 | 17 | 0.310 |
Why?
|
| Retrospective Studies | 12 | 2024 | 17363 | 0.310 |
Why?
|
| Risk Factors | 14 | 2020 | 10910 | 0.310 |
Why?
|
| Diphtheria | 1 | 2009 | 17 | 0.310 |
Why?
|
| Tetanus | 1 | 2009 | 22 | 0.310 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 311 | 0.300 |
Why?
|
| Measles | 1 | 2009 | 43 | 0.300 |
Why?
|
| Cost of Illness | 2 | 2020 | 275 | 0.290 |
Why?
|
| Incidence | 8 | 2025 | 3361 | 0.290 |
Why?
|
| Immunologic Tests | 1 | 2008 | 17 | 0.290 |
Why?
|
| Medical Records | 1 | 2009 | 189 | 0.290 |
Why?
|
| Geographic Information Systems | 1 | 2008 | 42 | 0.290 |
Why?
|
| Surveys and Questionnaires | 7 | 2020 | 3980 | 0.280 |
Why?
|
| Child Development | 1 | 2011 | 288 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1305 | 0.280 |
Why?
|
| Malnutrition | 1 | 2011 | 221 | 0.280 |
Why?
|
| Signal Transduction | 1 | 2020 | 4725 | 0.280 |
Why?
|
| Immunization | 1 | 2009 | 312 | 0.270 |
Why?
|
| Schistosomiasis | 2 | 2018 | 54 | 0.270 |
Why?
|
| Ascaris lumbricoides | 3 | 2018 | 19 | 0.270 |
Why?
|
| Hepatitis B | 1 | 2009 | 171 | 0.270 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 323 | 0.270 |
Why?
|
| United States | 10 | 2023 | 11627 | 0.270 |
Why?
|
| Environment | 1 | 2008 | 154 | 0.270 |
Why?
|
| Caregivers | 2 | 2024 | 598 | 0.260 |
Why?
|
| Prevalence | 8 | 2025 | 2664 | 0.260 |
Why?
|
| Meningitis, Viral | 1 | 2006 | 10 | 0.260 |
Why?
|
| Encephalitis, Viral | 1 | 2006 | 21 | 0.250 |
Why?
|
| Vaccination | 4 | 2024 | 1017 | 0.250 |
Why?
|
| Logistic Models | 5 | 2020 | 1840 | 0.250 |
Why?
|
| Cost-Benefit Analysis | 3 | 2014 | 557 | 0.240 |
Why?
|
| Odds Ratio | 5 | 2017 | 1256 | 0.240 |
Why?
|
| Biomarkers | 4 | 2025 | 3389 | 0.240 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 748 | 0.240 |
Why?
|
| Immune Tolerance | 2 | 2024 | 153 | 0.240 |
Why?
|
| Developing Countries | 6 | 2024 | 288 | 0.230 |
Why?
|
| Luminescent Measurements | 1 | 2025 | 60 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2007 | 329 | 0.220 |
Why?
|
| Masks | 1 | 2024 | 40 | 0.220 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 47 | 0.220 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 1502 | 0.220 |
Why?
|
| Middle Aged | 12 | 2025 | 28888 | 0.220 |
Why?
|
| Philippines | 2 | 2020 | 23 | 0.210 |
Why?
|
| Tuberculosis Vaccines | 1 | 2023 | 13 | 0.210 |
Why?
|
| Ohio | 4 | 2008 | 87 | 0.210 |
Why?
|
| Bias | 2 | 2021 | 144 | 0.210 |
Why?
|
| Public Health | 2 | 2019 | 282 | 0.200 |
Why?
|
| Oximetry | 1 | 2024 | 179 | 0.200 |
Why?
|
| Registries | 3 | 2017 | 1585 | 0.200 |
Why?
|
| Hypoxia | 1 | 2024 | 261 | 0.190 |
Why?
|
| Levonorgestrel | 1 | 2022 | 20 | 0.190 |
Why?
|
| Child Health | 1 | 2023 | 69 | 0.190 |
Why?
|
| Tuberculosis, Bovine | 1 | 2021 | 1 | 0.180 |
Why?
|
| Aerosols | 1 | 2022 | 64 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 61 | 0.180 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2021 | 12 | 0.180 |
Why?
|
| HIV | 1 | 2023 | 190 | 0.180 |
Why?
|
| False Negative Reactions | 1 | 2021 | 89 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 295 | 0.180 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 152 | 0.180 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 1451 | 0.170 |
Why?
|
| False Positive Reactions | 1 | 2021 | 143 | 0.170 |
Why?
|
| Disasters | 1 | 2022 | 105 | 0.170 |
Why?
|
| Goals | 1 | 2022 | 134 | 0.170 |
Why?
|
| Systems Biology | 1 | 2021 | 62 | 0.170 |
Why?
|
| Botswana | 1 | 2021 | 76 | 0.170 |
Why?
|
| Confidence Intervals | 1 | 2021 | 278 | 0.170 |
Why?
|
| Africa | 1 | 2021 | 140 | 0.170 |
Why?
|
| Molecular Typing | 1 | 2020 | 34 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 42 | 0.170 |
Why?
|
| Cough | 1 | 2021 | 97 | 0.170 |
Why?
|
| Alanine | 1 | 2020 | 183 | 0.160 |
Why?
|
| Schistosoma | 2 | 2017 | 13 | 0.160 |
Why?
|
| Earthquakes | 1 | 2019 | 5 | 0.160 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 95 | 0.160 |
Why?
|
| Drug Interactions | 1 | 2020 | 246 | 0.160 |
Why?
|
| Child Welfare | 2 | 2011 | 67 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2020 | 209 | 0.160 |
Why?
|
| Lesotho | 1 | 2019 | 17 | 0.160 |
Why?
|
| Malawi | 1 | 2021 | 426 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 722 | 0.150 |
Why?
|
| Preventive Medicine | 1 | 2019 | 21 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 1205 | 0.150 |
Why?
|
| Chloroquine | 1 | 1999 | 31 | 0.150 |
Why?
|
| Adolescent Behavior | 1 | 2020 | 171 | 0.150 |
Why?
|
| Fever | 1 | 2021 | 312 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 897 | 0.150 |
Why?
|
| Transcriptome | 2 | 2022 | 1125 | 0.150 |
Why?
|
| Cyclonic Storms | 1 | 2019 | 79 | 0.150 |
Why?
|
| Weight Gain | 1 | 2021 | 408 | 0.150 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 17 | 0.140 |
Why?
|
| Puerto Rico | 1 | 2018 | 52 | 0.140 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 87 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2018 | 77 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2023 | 825 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 382 | 0.140 |
Why?
|
| Early Diagnosis | 2 | 2016 | 198 | 0.140 |
Why?
|
| United Kingdom | 2 | 2023 | 234 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2018 | 159 | 0.130 |
Why?
|
| Tuberculin | 1 | 2017 | 7 | 0.130 |
Why?
|
| Health Education | 2 | 2017 | 232 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2020 | 361 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 55 | 0.130 |
Why?
|
| Attitude | 1 | 2017 | 120 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2020 | 1570 | 0.130 |
Why?
|
| Helminthiasis | 1 | 2017 | 78 | 0.130 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 656 | 0.130 |
Why?
|
| Calibration | 1 | 2016 | 99 | 0.130 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 585 | 0.130 |
Why?
|
| Antibodies, Helminth | 2 | 2016 | 125 | 0.120 |
Why?
|
| Research Design | 2 | 2012 | 750 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 503 | 0.120 |
Why?
|
| Sex Factors | 1 | 2020 | 1353 | 0.120 |
Why?
|
| Anthelmintics | 1 | 2016 | 55 | 0.120 |
Why?
|
| International Cooperation | 2 | 2011 | 166 | 0.120 |
Why?
|
| Housing | 2 | 2013 | 54 | 0.120 |
Why?
|
| Immunoglobulin E | 2 | 2016 | 180 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 747 | 0.120 |
Why?
|
| Time Factors | 3 | 2016 | 6455 | 0.120 |
Why?
|
| Comorbidity | 1 | 2020 | 1605 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 95 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 245 | 0.120 |
Why?
|
| Schools | 1 | 2017 | 238 | 0.120 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 188 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 626 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2020 | 822 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2016 | 184 | 0.110 |
Why?
|
| Somalia | 2 | 2025 | 6 | 0.110 |
Why?
|
| Resource Allocation | 1 | 2014 | 53 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 348 | 0.110 |
Why?
|
| Health Promotion | 1 | 2017 | 404 | 0.110 |
Why?
|
| Age Distribution | 2 | 2005 | 433 | 0.100 |
Why?
|
| Europe | 2 | 2025 | 373 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1261 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2016 | 414 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2017 | 1230 | 0.090 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 67 | 0.090 |
Why?
|
| Morbidity | 1 | 2012 | 255 | 0.090 |
Why?
|
| Markov Chains | 1 | 2012 | 99 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2025 | 3421 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 156 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 693 | 0.090 |
Why?
|
| Financing, Organized | 1 | 2011 | 21 | 0.090 |
Why?
|
| World Health Organization | 2 | 2025 | 119 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2025 | 239 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 88 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2011 | 53 | 0.080 |
Why?
|
| Child Health Services | 1 | 2011 | 87 | 0.080 |
Why?
|
| Urban Health Services | 1 | 2010 | 22 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 182 | 0.080 |
Why?
|
| Russia | 1 | 2009 | 38 | 0.080 |
Why?
|
| Guatemala | 1 | 2009 | 63 | 0.080 |
Why?
|
| Documentation | 1 | 2010 | 121 | 0.080 |
Why?
|
| Aged | 6 | 2024 | 21379 | 0.070 |
Why?
|
| China | 1 | 2009 | 290 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 947 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2011 | 494 | 0.070 |
Why?
|
| Consensus | 2 | 2025 | 656 | 0.070 |
Why?
|
| Nutrition Assessment | 1 | 2008 | 136 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2008 | 179 | 0.070 |
Why?
|
| Animals | 8 | 2024 | 34989 | 0.070 |
Why?
|
| Demography | 1 | 2008 | 242 | 0.070 |
Why?
|
| Minnesota | 1 | 2007 | 179 | 0.070 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 77 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2019 | 149 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2008 | 7111 | 0.070 |
Why?
|
| Interleukin-4 | 2 | 2018 | 147 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2008 | 436 | 0.070 |
Why?
|
| Asia | 2 | 2019 | 126 | 0.060 |
Why?
|
| Prognosis | 1 | 2016 | 5009 | 0.060 |
Why?
|
| Child Nutrition Disorders | 1 | 2007 | 77 | 0.060 |
Why?
|
| Bacterial Proteins | 2 | 2008 | 929 | 0.060 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2025 | 19 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2008 | 415 | 0.060 |
Why?
|
| Cognition | 1 | 2011 | 814 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2005 | 216 | 0.060 |
Why?
|
| Succinates | 1 | 2024 | 19 | 0.060 |
Why?
|
| Succinic Acid | 1 | 2024 | 13 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2024 | 29 | 0.060 |
Why?
|
| Everolimus | 1 | 2024 | 50 | 0.050 |
Why?
|
| Microscopy | 2 | 2016 | 125 | 0.050 |
Why?
|
| European Union | 1 | 2023 | 13 | 0.050 |
Why?
|
| Health Behavior | 1 | 2007 | 399 | 0.050 |
Why?
|
| Saliva | 1 | 2024 | 133 | 0.050 |
Why?
|
| Urban Population | 2 | 2017 | 243 | 0.050 |
Why?
|
| Cytokines | 2 | 2022 | 1368 | 0.050 |
Why?
|
| Poverty | 2 | 2019 | 437 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 311 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 686 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2004 | 324 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 406 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 803 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 62 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 826 | 0.050 |
Why?
|
| Triage | 1 | 2023 | 148 | 0.050 |
Why?
|
| Oxazines | 1 | 2021 | 26 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 73 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 40 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2021 | 120 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2021 | 176 | 0.040 |
Why?
|
| Trichomonas Vaginitis | 1 | 2020 | 14 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 13016 | 0.040 |
Why?
|
| Gastrointestinal Contents | 1 | 2020 | 13 | 0.040 |
Why?
|
| Gonorrhea | 1 | 2020 | 40 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 49 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 130 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 273 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 576 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 387 | 0.040 |
Why?
|
| South America | 1 | 2019 | 42 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2019 | 20 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 478 | 0.040 |
Why?
|
| Piperazines | 1 | 2021 | 254 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 759 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 1999 | 34 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1999 | 33 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 549 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2020 | 250 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 67 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 175 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2017 | 69 | 0.030 |
Why?
|
| Urine | 1 | 2017 | 92 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2017 | 22 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 478 | 0.030 |
Why?
|
| Malaria | 1 | 2017 | 103 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1484 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2016 | 29 | 0.030 |
Why?
|
| Phagosomes | 1 | 2016 | 38 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1720 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2016 | 92 | 0.030 |
Why?
|
| Thorax | 1 | 2015 | 73 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 344 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 410 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 193 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 220 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1707 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1526 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 135 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2016 | 188 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1647 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5405 | 0.030 |
Why?
|
| Americas | 1 | 2014 | 52 | 0.030 |
Why?
|
| Lysosomes | 1 | 2016 | 262 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 806 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1153 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 351 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 449 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1652 | 0.020 |
Why?
|
| Microbial Interactions | 1 | 2012 | 16 | 0.020 |
Why?
|
| Health Policy | 1 | 2014 | 230 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3062 | 0.020 |
Why?
|
| Community Health Centers | 1 | 2011 | 40 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1247 | 0.020 |
Why?
|
| Medical Audit | 1 | 2011 | 101 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 165 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2512 | 0.020 |
Why?
|
| Community Health Services | 1 | 2011 | 93 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 263 | 0.020 |
Why?
|
| Health Resources | 1 | 2011 | 129 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 455 | 0.020 |
Why?
|
| Internship and Residency | 1 | 1999 | 1252 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2556 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 6248 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 680 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2018 | 2494 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 204 | 0.020 |
Why?
|
| Clothing | 1 | 2007 | 12 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 18571 | 0.020 |
Why?
|
| Insect Repellents | 1 | 2007 | 36 | 0.020 |
Why?
|
| Insecticides | 1 | 2007 | 62 | 0.020 |
Why?
|
| Television | 1 | 2007 | 71 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2007 | 101 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 2706 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 4545 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 1999 | 197 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 564 | 0.010 |
Why?
|